header image

Brian D. Herman, PhD



Dr. Brian Herman

Contact

S810 Scaife Hall

Mentor

Dr. Nicolas Sluis-Cremer

Education

PhD in Molecular Virology and Microbiology, University of Pittsburgh, School of Medicine, 2012

BS in Biology (Minor in German Language), Allegheny College, 2005


Research

Areas of Interest

Novel antiviral small molecule drug development; HIV-1 and HCV drug resistance; viral and human DNA polymerase substrate usage and kinetics

Abstracts

Herman BD, Zhang H-W, Coats S, Schinazi R, Mellors J, and N Sluis-Cremer. The 5’-triphosphates of 3’-azido-2’,3’-dideoxyguanosine and 3’-azido-2,6-diamino-2’,3’-dideoxypurine act synergistically to inhibit wild-type and NRTI-resistant HIV-1 reverse transcriptase. 18th Conference on Retroviruses and Opportunistic Infections February 27- March 2, 2011, Boston, MA USA.

Herman BD, Obikhod A, Asif G, Zhang H-W, Coats SJ, Schinazi RF, Mellors JW, and N Sluis-Cremer. RS-788, a Prodrug of β-D-3’-Azido-2,6-diamino-2’,3’-dideoxypurine, Exhibits Potent Activity Against NRTI-Resistant HIV-1. 17th Conference on Retroviruses and Opportunistic Infections February 16-19, 2010, San Francisco, CA USA.

Herman BD, Obikhod A, M Detorio, Zhang H-W, Nettles J, Coats SJ, Schinazi RF, Mellors JW, and N Sluis-Cremer. Structure-activity-resistance relationships of 6-modified 3’-azido-2’,3’-dideoxyguanosine nucleotides as inhibitors of HIV-1 reverse transcriptase. Antiviral Therapy 2009; 14 Suppl 1:A144. XVIII international HIV Drug Resistance Workshop June 9-13, 2009 Fort Myers, Fl, USA.

Herman BD, Meteer J, Balzarini J, and N Sluis-Cremer. Mechanism of action and resistance to PMEO-5-methyl-DAPy, a novel pyrimidine nucleotide reverse transcriptase inhibitor. 9th Annual Symposium on Antiviral Drug Resistance: Targets and Mechanisms, November 16-19, 2008 Richmond, VA. USA.

Schinazi RF, Coats SJ, Zhang H-W, Detorio M, Obikhod A, Asif G, Herman BD, Nettles JH, Sluis-Cremer N, and JW Mellors. β-D-3’-Azido-2,6-diamino-2’,3’-dideoxypurine (AZD) is a potent inhibitor of HIV-1 and is bioconverted intracellularly to both AZD-TP and its guanosine-5’-triphosphate form. 15th Conference on Retroviruses and Opportunistic Infections February 3-6, 2008, Boston, MA USA.

Sluis-Cremer N, Koontz D, Herman BD, Hernandez-Santiago, Rapp KL, Amblard F, Bondada L, Coats SJ, Schinazi RF and JW Mellors. Discovery, structure-activity-resistance relationships, and pharmacology of the 3’-azido-2’, 3’-dideoxypurines, a potent lead class of nucleoside analogs active against drug-resistant HIV-1. 9th Annual Symposium on Antiviral Drug Resistance: Targets and Mechanisms, November 16-19, 2008 Richmond, VA. USA.

BD Herman, Lamirande EW, Chen J, Vogel L, Subbarao K, and A Roberts. Real Time RT-PCR Analysis of Cytokine Responses to a Mouse-adapted SARS Coronavirus Infection. Road to Discovery Summer Research Program 2005 Student Poster Session. NIH Clinical Center Bethesda, MD August 4, 2005

Why I chose Pitt

I chose to complete my graduate studies at the University of Pittsburgh School of Medicine Interdisciplinary Biomedical Graduate Program because of the opportunity to work with accomplished and renowned researchers from a wide range of disciplines. Additionally, Pittsburgh is an excellent city to live in during a graduate career.

Following his graduation, Brian accepted a position as a Postdoctoral Associate in the lab of his mentor, Dr. Nicolas Sluis-Cremer, in the Department of Medicine, Division of Infectious Diseases.